Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

• Cristina Candal-Pedreira ^[1] ; Alberto Ruano-Ravina ^[1] ; Virginia Calvo de Juan ^[2] ; Manuel Cobo ^[3] ; José Manuel Trigo ^[3] ; Delvys Rodríguez-Abreu ^[4] ; Anna Estival ^[4] ; Enric Carcereny ^[5] ; Marc Cucurull ^[5] ; Rafael López Castro ^[6] ; Andrea Medina ^[6] ; Rosario García Campelo ^[7] ; Patricia Cordeiro González ^[7] ; Amparo Sánchez-Gastaldo ^[8] ; Joaquim Bosch-Barrera ^[9] ; Bartomeu Massutí ^[10] ; Manuel Dómine ^[11] ; Carlos Camps ^[12] ; Ana Laura Ortega ^[13] ; Alfredo Sánchez-Hernández ^[14] ; María Guirado Risueño ^[15] ; Edel del Barco Morillo ^[16] ; Alberto Garrido Fernández ^[17] ; Mariano Provencio ^[2]
  1. [1] Universidade de Santiago de Compostela

     Universidade de Santiago de Compostela

     Santiago de Compostela, España

     
  2. [2] Oncology Department, Puerta de Hierro University Teaching Hospital, Majadahonda, Spain
  3. [3] UGC Medical Oncology Intercenters, Regional and Virgen de la Victoria University Teaching Hospitals, Malaga, IBIMA, Malaga, Spain
  4. [4] Gran Canaria Island Hospital, Las Palmas de Gran Canaria, Spain
  5. [5] Medical Oncology Department, Catalonian Oncology Institute, Badalona-Germans Trias i Pujol Hospital, B-ARGO Group, Spain
  6. [6] Medical Oncology Section, Valladolid University Clinical Teaching Hospital, Spain
  7. [7] Department of Oncology, A Coruña University Teaching Hospital Complex, Coruña, Spain
  8. [8] Virgen del Rocio University Teaching Hospital, Seville, Spain
  9. [9] Catalonian Oncology Institute, Dr. Josep Trueta University Teaching Hospital, Girona, Spain
  10. [10] Dr. Balmis University Teaching Hospital, Alicante Health Research and Biomedical Institute (ISABIAL), Alicante, Spain
  11. [11] Jiménez Díaz Foundation University Hospital, IIS-FJD, Madrid, Spain
  12. [12] Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital and Precision Oncology Group (OncoGIR-Pro), Girona Biomedical Research Institute (IDIBGI), Girona, Spain
  13. [13] Jaén Hospital Complex, Jaén, Spain
  14. [14] Castellón Provincial Hospital, Castellón, Spain
  15. [15] Department of Oncology, Elche University General Teaching Hospital, Elche, Spain
  16. [16] Medical Oncology Department, Salamanca University Healthcare Complex-IBSAL, Salamanca, Spain
  17. [17] Álvaro Cunqueiro University Teaching Hospital, Vigo, Spain

  Mostrar afiliaciones +
• Localización: Archivos de bronconeumología: Organo oficial de la Sociedad Española de Neumología y Cirugía Torácica SEPAR y la Asociación Latinoamericana de Tórax ( ALAT ), ISSN 0300-2896, Vol. 60, Nº. 2, 2024, págs. 88-94
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction The aim of this study was to analyze the clinical and genetic characteristics of young lung cancer cases, and to compare them with those of older cases.

    Methods We used the Thoracic Tumors Registry (TTR) as a data source representative of lung cancer cases diagnosed in Spain, and included all cases registered until 9/01/2023 which had information on age at diagnosis or the data needed to calculate it. We performed a descriptive statistical analysis and fitted logistic regressions to analyze how different characteristics influenced being a younger lung cancer patient.

    Results A total of 26,336 subjects were included. Lung cancer cases <50 years old had a higher probability of being women (OR: 1.38; 95% CI: 1.21–1.57), being in stage III or IV (OR: 1.32; 95% CI: 1.08–1.62), not having comorbidities (OR: 5.21; 95% CI: 4.59–5.91), presenting with symptoms at diagnosis (OR: 1.53; 95% CI: 1.29–1.81), and having ALK translocation (OR: 7.61; 95% CI: 1.25–46.32) and HER2 mutation (OR: 5.71; 95% CI: 1.34–24.33), compared with subjects ≥50 years. Among subjects <35 years old (n = 61), our study observed a higher proportion of women (59.0% vs. 26.6%; p < 0.001), never smokers (45.8% vs. 10.3%; p < 0.001), no comorbidities (21.3% vs. 74.0%; p < 0.001); ALK translocation (33.3% vs. 4.4%; p < 0.001) and ROS1 mutation (14.3% vs. 2.3%; p = 0.01), compared with subjects ≥35 years.

    Conclusions Lung cancer displays differences by age at diagnosis which may have important implications for its clinical management.